Table of Contents Author Guidelines Submit a Manuscript
Pain Research and Treatment
Volume 2012, Article ID 953140, 6 pages
http://dx.doi.org/10.1155/2012/953140
Research Article

A New Drug Release Method in Early Development of Transdermal Drug Delivery Systems

1Division for Applied Materials Science, Department of Engineering Sciences, The Ångström Laboratory, Uppsala University, Box 534, 751 21 Uppsala, Sweden
2Department of Analytical Chemistry, Orexo AB, P.O. Box 303, 751 05 Uppsala, Sweden

Received 11 May 2012; Accepted 28 June 2012

Academic Editor: Howard Smith

Copyright © 2012 Bing Cai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. E. Aulton, Aulton's Pharmaceutics: The Design and Manufacture of Medicines, Churchill Livingstone, Edinburgh, NY, USA, 3rd edition, 2007.
  2. M. R. Prausnitz, S. Mitragotri, and R. Langer, “Current status and future potential of transdermal drug delivery,” Nature Reviews Drug Discovery, vol. 3, no. 2, pp. 115–124, 2004. View at Google Scholar · View at Scopus
  3. M. R. Prausnitz and R. Langer, “Transdermal drug delivery,” Nature Biotechnology, vol. 26, no. 11, pp. 1261–1268, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Hadgraft, D. Beutner, and H. M. Wolff, “In vivo-in vitro comparisons in the transdermal delivery of nitroglycerin,” International Journal of Pharmaceutics, vol. 89, no. 1, pp. R1–R4, 1993. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Prodduturi, G. J. Smith, A. M. Wokovich, W. H. Doub, B. J. Westenberger, and L. Buhse, “Reservoir based fentanyl transdermal drug delivery systems: effect of patch age on drug release and skin permeation,” Pharmaceutical Research, vol. 26, no. 6, pp. 1344–1352, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. L. V. Allen Jr., “Transdermals: the skin as part of a drug delivery system,” International Journal of Pharmaceutical Compounding, vol. 15, no. 4, pp. 308–315, 2011. View at Google Scholar · View at Scopus
  7. H. A. E. Benson, “Transdermal drug delivery: penetration enhancement techniques,” Current Drug Delivery, vol. 2, no. 1, pp. 23–33, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. O. Anand, L. X. Yu, D. P. Conner, and B. M. Davit, “Dissolution testing for generic drugs: an FDA perspective,” Aaps Journal, vol. 13, no. 3, pp. 328–335, 2011. View at Google Scholar
  9. C. Tong, R. Lozano, Y. Mao et al., “The value of in Vitro dissolution in drug development: a position paper from the AAPS in Vitro release and dissolution focus group,” Pharmaceutical Technology, vol. 33, no. 4, pp. 52–64, 2009. View at Google Scholar · View at Scopus
  10. C. T. Ueda, M. Marques, V. P. Shah et al., “Topical and transdermal drug products,” Pharmacopeial Forum, vol. 35, no. 3, pp. 750–764, 2009. View at Google Scholar · View at Scopus
  11. R. O. Salama, D. Traini, H. K. Chan, and P. M. Young, “Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 70, no. 1, pp. 145–152, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Costa, “An alternative method to the evaluation of similarity factor in dissolution testing,” International Journal of Pharmaceutics, vol. 220, no. 1-2, pp. 77–83, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. R. H. Guy and J. Hadgraft, “Rate control in transdermal drug delivery?” International Journal of Pharmaceutics, vol. 82, no. 3, pp. R1–R6, 1992. View at Publisher · View at Google Scholar · View at Scopus
  14. J. C. Olivier, S. Rabouan, and W. Couet, “In vitro comparative studies of two marketed transdermal nicotine delivery systems: nicopatch and Nicorette,” International Journal of Pharmaceutics, vol. 252, no. 1-2, pp. 133–140, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Azarmi, W. Roa, and R. Löbenberg, “Current perspectives in dissolution testing of conventional and novel dosage forms,” International Journal of Pharmaceutics, vol. 328, no. 1, pp. 12–21, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Azarmi, W. Roa, and R. Löbenberg, “Current perspectives in dissolution testing of conventional and novel dosage forms,” International Journal of Pharmaceutics, vol. 328, no. 1, pp. 12–21, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. B. W. Kemppainen and W. G. Reifenrath, Methods for Skin Absorption, CRC Press, Boca Raton, Fla, USA, 1990.
  18. Y. Levintova, F. M. Plakogiannis, and R. A. Bellantone, “An improved in vitro method for measuring skin permeability that controls excess hydration of skin using modified Franz diffusion cells,” International Journal of Pharmaceutics, vol. 419, no. 1-2, pp. 96–106, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. D. A. Van Hal, E. Jeremiasse, H. E. Junginger, F. Spies, and J. A. Bouwstra, “Structure of fully hydrated human stratum corneum: a freeze-fracture electron microscopy study,” Journal of Investigative Dermatology, vol. 106, no. 1, pp. 89–95, 1996. View at Google Scholar · View at Scopus
  20. E. W. Smith and H. I. Maibach, Percutaneous Penetration Enhancers, CRC/Taylor & Francis, Boca Raton, Fla, USA, 2nd edition, 2006.
  21. A. M. MacConnachie, “Fentanyl transdermal (Durogesic, Janssen),” Intensive and Critical Care Nursing, vol. 11, no. 6, pp. 360–361, 1995. View at Google Scholar · View at Scopus
  22. R. B. R. Muijsers and A. J. Wagstaff, “Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control,” Drugs, vol. 61, no. 15, pp. 2289–2307, 2001. View at Google Scholar · View at Scopus
  23. V. Coopman, J. Cordonnier, K. Pien, and D. Van Varenbergh, “LC-MS/MS analysis of fentanyl and norfentanyl in a fatality due to application of multiple Durogesic transdermal therapeutic systems,” Forensic Science International, vol. 169, no. 2-3, pp. 223–227, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. G. K. Gourlay, S. R. Kowalski, J. L. Plummer, D. A. Cherry, P. Gaukroger, and M. J. Cousins, “The transdermal administration of fentanyl in the treatment of postoperative pain: pharmacokinetics and pharmacodynamic effects,” Pain, vol. 37, no. 2, pp. 193–202, 1989. View at Google Scholar · View at Scopus
  25. A. M. MacConnachie, “Analgesics in the management of chronic pain. Part five: step 3 parenteral analgesic drug therapy,” Intensive & Critical Care Nursing, vol. 15, no. 1, pp. 58–60, 1999. View at Google Scholar · View at Scopus
  26. J. E. Polli, G. S. Rekhi, L. L. Augsburger, and V. P. Shah, “Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets,” Journal of Pharmaceutical Sciences, vol. 86, no. 6, pp. 690–700, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. Note for guidance on the investigation of bioavailability and bioequivalence, C.f.p.m. products, T.e.a.f.t.e.o.m. products, and E.o.m.f.h. use, Ed, European Medicines Agency, London, UK, 2000.
  28. B. Documentation, “Guidance for industry? Immediate release solid oral dosage forms,” Pharmaceutical Process Scale-Up, vol. 118, p. 353, 2001. View at Google Scholar
  29. K. D. Mpharm, K. P. Mpharm, and S. Chakravarthi, “Preparation and evaluation of transdermal plasters containing norfloxacin: a novel treatment for burn wound healing,” Eplasty, vol. 10, article e44, 2010. View at Google Scholar
  30. S. T. Prajapati, C. G. Patel, and C. N. Patel, “Formulation and evaluation of transdermal patch of repaglinide,” ISRN Pharmaceutics, vol. 2011, Article ID 651909, 9 pages, 2011. View at Publisher · View at Google Scholar
  31. M. X. Zhou, D. Shoudt, G. Calderon, and M. Feng, “Application of USP apparatus 7 to in vitro drug release in scopolamine transdermal systems,” Dissolution Technologies, vol. 14, no. 2, pp. 25–30, 2007. View at Google Scholar
  32. V. P. Shah, Y. Tsong, P. Sathe, and J. P. Liu, “In vitro dissolution profile comparison—statistics and analysis of the similarity factor, f2,” Pharmaceutical Research, vol. 15, no. 6, pp. 889–896, 1998. View at Publisher · View at Google Scholar · View at Scopus
  33. R. H. Larsen, F. Nielsen, J. A. Sørensen, and J. B. Nielsen, “Dermal penetration of fentanyl: inter- and intraindividual variations,” Pharmacology and Toxicology, vol. 93, no. 5, pp. 244–248, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. S. D. Roy and G. L. Flynn, “Solubility behavior of narcotic analgesics in aqueous media: solubilities and dissociation constants of morphine, fentanyl, and sufentanil,” Pharmaceutical Research, vol. 6, no. 2, pp. 147–151, 1989. View at Google Scholar · View at Scopus